Abstract
Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.
Keywords: CGRP; migraine; pulmonary hypertension; right heart failure.
All Keywords
【저자키워드】 pulmonary hypertension, CGRP, migraine, right heart failure., 【초록키워드】 COVID-19, coronavirus, Trial, Cardiopulmonary, peptide, hypertension, heart failure, Early detection, Awareness, receptor, Coronavirus 2019, calcitonin, protective effect, pulmonary hypertension, Lung inflammation, migraine, receptor antagonists, adverse effect, calcitonin gene-related peptide, right heart failure, worsening, US FDA, antagonist, Prevent, raise, reduce, 【제목키워드】 antagonism, Adverse, Effect, Potential,
【저자키워드】 pulmonary hypertension, CGRP, migraine, right heart failure., 【초록키워드】 COVID-19, coronavirus, Trial, Cardiopulmonary, peptide, hypertension, heart failure, Early detection, Awareness, receptor, Coronavirus 2019, calcitonin, protective effect, pulmonary hypertension, Lung inflammation, migraine, receptor antagonists, adverse effect, calcitonin gene-related peptide, right heart failure, worsening, US FDA, antagonist, Prevent, raise, reduce, 【제목키워드】 antagonism, Adverse, Effect, Potential,
{{{ 추상적인 }}}
최근 미국 FDA는 코로나바이러스 2019(COVID-19)에서 폐 염증을 줄이기 위해 칼시토닌 유전자 관련 펩티드(CGRP) 수용체 길항제를 사용한 약물 용도 변경 시험을 승인했습니다. 그러나 CGRP의 잘 정립된 심폐 보호 효과는 COVID-19에서 CGRP를 길항하는 안전성에 대한 우려를 불러일으킵니다. 잠재적인 심폐 부작용에 대한 인식은 조기 발견을 가능하게 하고 질병이 악화되는 것을 예방할 수 있습니다.
{{ 키워드: }} CGRP; 편두통; 폐 고혈압; 오른쪽 심장 마비.